Next Article in Journal
Untargeted Metabolomics Reveal Defensome-Related Metabolic Reprogramming in Sorghum bicolor against Infection by Burkholderia andropogonis
Previous Article in Journal
Brain Metabolomics Reveal the Antipyretic Effects of Jinxin Oral Liquid in Young Rats by Using Gas Chromatography–Mass Spectrometry
Open AccessArticle

Palbociclib and Fulvestrant Act in Synergy to Modulate Central Carbon Metabolism in Breast Cancer Cells

1
The Scripps Research Institute, Scripps Center for Metabolomics and Mass Spectrometry, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
2
Department of Food Chemistry and Toxicology, Faculty of Chemistry, University of Vienna, Währingerstraße 38, 1090 Vienna, Austria
3
Vienna Metabolomics Center (VIME), University of Vienna, 1090 Vienna, Austria
4
Department of Environmental Health Sciences, Yale School of Public Health, Yale University, New Haven, CT 06511, USA
5
Oncology Research, Pfizer Worldwide Research and Development, San Diego, CA 92121, USA
*
Author to whom correspondence should be addressed.
Metabolites 2019, 9(1), 7; https://doi.org/10.3390/metabo9010007
Received: 6 November 2018 / Revised: 19 December 2018 / Accepted: 21 December 2018 / Published: 2 January 2019
The aims of this study were to determine whether combination chemotherapeutics exhibit a synergistic effect on breast cancer cell metabolism. Palbociclib, is a selective inhibitor of cyclin-dependent kinases 4 and 6, and when patients are treated in combination with fulvestrant, an estrogen receptor antagonist, they have improved progression-free survival. The mechanisms for this survival advantage are not known. Therefore, we analyzed metabolic and transcriptomic changes in MCF-7 cells following single and combination chemotherapy to determine whether selective metabolic pathways are targeted during these different modes of treatment. Individually, the drugs caused metabolic disruption to the same metabolic pathways, however fulvestrant additionally attenuated the pentose phosphate pathway and the production of important coenzymes. A comprehensive effect was observed when the drugs were applied together, confirming the combinatory therapy’s synergism in the cell model. This study also highlights the power of merging high-dimensional datasets to unravel mechanisms involved in cancer metabolism and therapy. View Full-Text
Keywords: combination drug therapy; breast cancer; multi-omics; metabolomics; RNA-seq; XCMS Online combination drug therapy; breast cancer; multi-omics; metabolomics; RNA-seq; XCMS Online
Show Figures

Graphical abstract

MDPI and ACS Style

Warth, B.; Palermo, A.; Rattray, N.J.; Lee, N.V.; Zhu, Z.; Hoang, L.T.; Cai, Y.; Mazurek, A.; Dann, S.; VanArsdale, T.; Fantin, V.R.; Shields, D.; Siuzdak, G.; Johnson, C.H. Palbociclib and Fulvestrant Act in Synergy to Modulate Central Carbon Metabolism in Breast Cancer Cells. Metabolites 2019, 9, 7.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map

1
Back to TopTop